Edition:
United States

Loxo Oncology Inc (LOXO.OQ)

LOXO.OQ on NASDAQ Stock Exchange Global Market

166.50USD
11:54am EDT
Change (% chg)

$-0.25 (-0.15%)
Prev Close
$166.75
Open
$167.33
Day's High
$167.80
Day's Low
$160.77
Volume
36,015
Avg. Vol
137,596
52-wk High
$208.78
52-wk Low
$71.45

Chart for

About

Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.... (more)

Overall

Beta: 2.24
Market Cap(Mil.): $5,080.88
Shares Outstanding(Mil.): 30.47
Dividend: --
Yield (%): --

Financials

  LOXO.OQ Industry Sector
P/E (TTM): -- 113.18 32.94
EPS (TTM): -3.65 -- --
ROI: -22.03 1.56 12.84
ROE: -25.60 0.73 14.95

Bayer open for drug licensing deals, cutting debt remains priority

FRANKFURT Bayer is ready to spend money on more drug licensing agreements like last year's deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

Sep 05 2018

Bayer open for drug licensing deals, cutting debt remains priority

FRANKFURT, Sept 5 Bayer is ready to spend money on more drug licensing agreements like last year's deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

Sep 05 2018

Loxo-Bayer cancer drug gets priority review from FDA

Loxo Oncology and Bayer AG said on Tuesday the U.S. Food and Drug Administration granted priority review to their cancer drug and would decide on the marketing application by Nov. 26.

May 29 2018

Loxo-Bayer cancer drug gets priority review from FDA

May 29 Loxo Oncology and Bayer AG said on Tuesday the U.S. Food and Drug Administration granted priority review to their cancer drug and would decide on the marketing application by Nov. 26.

May 29 2018

Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

May 17 2018

CORRECTED-UPDATE 1-Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO, May 16 An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

May 17 2018

Loxo Oncology's targeted RET drug shows promise in early trial

CHICAGO, May 16 An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

May 16 2018

BRIEF-Loxo Oncology Reports Qtrly Loss Per Share Of $0.12

* LOXO ONCOLOGY - AS OF MARCH 31, 2018, CO HAD AGGREGATE CASH, CASH EQUIVALENTS AND INVESTMENTS OF $735.6 MILLION, COMPARED TO $626.2 MILLION AS OF DEC 31, 2017

May 08 2018

BRIEF-Veracyte Announces Precision Medicine Collaboration With Loxo Oncology

* VERACYTE ANNOUNCES PRECISION MEDICINE COLLABORATION WITH LOXO ONCOLOGY

Apr 11 2018

Loxo, Illumina to partner for diagnostic tool targeting cancer

Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types.

Apr 10 2018

Earnings vs. Estimates